Breaking News Instant updates and real-time market news.

DPLO

Diplomat Pharmacy

$20.31

0.3 (1.50%)

16:59
11/06/18
11/06
16:59
11/06/18
16:59

Diplomat Pharmacy reports Q3 EPS 0c, consensus 22c

Reports Q3 revenue $1.373B, consensus $1.42B. EPS was affected by an $8.1M increase in interest expense due to a significant increase in outstanding debt to fund our PBM acquisitions, partially offset by a $7.6M increase in income from operations.

  • 06

    Nov

DPLO Diplomat Pharmacy
$20.31

0.3 (1.50%)

07/23/18
WBLR
07/23/18
NO CHANGE
WBLR
Outperform
Diplomat Pharmacy recent selloff overdone, says William Blair
William Blair analyst John Kreger attributes the 20% pullback in shares of Diplomat Pharmacy from the June highs to growing concerns about the company's exposure to pharmaceutical rebates, which the Trump administration is seeking to regulate as part of a broader effort to lower drug prices for consumers. The analyst views the recent selloff as overdone. The vast majority of Diplomat's newly acquired pharmacy benefit management business is with commercial clients, rather than from Medicaid or Medicare Part D, Kreger tells investors in a research note. As such, any new regulations out of the Trump administration would presumably not affect PBM dealings with commercial clients, at least not directly, the analyst adds. Further, the analyst notes that rebates are just one of three broad ways in which PBMs are compensated by their clients. The other two are administrative per-claim fees and spread pricing on dispensed prescriptions. If rebates become less popular, the economics of the business could quickly shift to other payment mechanisms such as higher per-claim fees, Kreger contends. He does not view regulation of drug rebates as a long-term threat to the economics of the PBM business model for Diplomat or its larger peers. The analyst keeps an Outperform rating on Diplomat Pharmacy.
08/09/18
JPMS
08/09/18
NO CHANGE
Target $27
JPMS
Overweight
Diplomat Pharmacy selloff creates good entry point, says JPMorgan
After hosting investor meetings with management, JPMorgan analyst Lisa Gill says the recent pullback in shares of Diplomat Pharmacy provides a good entry point. The meetings were positive with management highlighting the growth opportunities in both the specialty and pharmacy benefit management businesses, Gill tells investors in a research note. Further, she viewed the company's commentary as favorable around the potential impact of President Trump's drug price blueprint. The analyst reiterates an Overweight rating on Diplomat Pharmacy with a $27 price target.
09/25/18
JPMS
09/25/18
NO CHANGE
JPMS
Overweight
Diplomat Pharmacy weakness on Gilead generics overdone, says JPMorgan
JPMorgan analyst Lisa Gill says the weakness yesterday in shares of Diplomat Pharmacy (DPLO) following Gilead's (GILD) announcement that it will be launching new authorized generic versions of hepatitis C treatments Epclusa and Harvoni is a "significant overreaction." Hepatitis C represents a relatively small portion of revenue for Diplomat Pharmacy, and as such, these two drugs are not material, Gill tells investors in a research note. Further, the analyst believes it is unclear whether payors will adopt the authorized generic in lieu of continuing to receive rebates on the branded drugs. In addition, Gill thinks Diplomat should be able to purchase the new authorized generics at a discount to the new list price with a higher gross margin spread relative to the brand. The analyst keeps an Overweight rating on the shares.
10/08/18
LSCM
10/08/18
NO CHANGE
Target $35
LSCM
Buy
Lake Street affirms Buy on Diplomat Pharmacy after talking to management
After speaking with CEO Brian Griffin and CFO Atul Kavthekar, Lake Street analyst Brooks O'Neil affirms a Buy rating on Diplomat Pharmacy with a $35 price target. The integration of last years' pharmacy benefit manager acquisitions continues to go very well and tailwinds "which have been blowing for DPLO have continued to blow," O'Neil tells investors in a research note. The analyst believes political and media rhetoric about changing rules for rebates in pharmacy services are unlikely to change the basic economics of the business. This type of "noise/activity has characterized the industry for several decades," the analyst contends. He expects "solid fundamentals" to continue to drive shares of Diplomat Pharmacy.

TODAY'S FREE FLY STORIES

02:35
11/16/18
11/16
02:35
11/16/18
02:35
General news
FX Update: The Dollar has traded broadly softer »

FX Update: The Dollar…

01:45
11/16/18
11/16
01:45
11/16/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

VIAB

Viacom

$31.87

0.07 (0.22%)

, VIA

Viacom

$36.09

0.76 (2.15%)

20:25
11/15/18
11/15
20:25
11/15/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

VIAB

Viacom

$31.87

0.07 (0.22%)

VIA

Viacom

$36.09

0.76 (2.15%)

HP

Helmerich & Payne

$60.05

1.75 (3.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 16

    Nov

  • 16

    Nov

  • 04

    Dec

TECK

Teck Resources

$22.04

0.9 (4.26%)

20:23
11/15/18
11/15
20:23
11/15/18
20:23
Hot Stocks
Teck Resources announces $400M stock buyback »

Teck Resources Board has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIX

Edison International

$47.07

-6.84 (-12.69%)

20:22
11/15/18
11/15
20:22
11/15/18
20:22
Hot Stocks
Edison International provides update on California fire restoration efforts »

Southern California…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRX

Valeritas

$0.47

-0.18 (-27.67%)

20:20
11/15/18
11/15
20:20
11/15/18
20:20
Syndicate
Valeritas 75M share Secondary priced at $0.48 »

Valeritas Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVMXY

Avita Medical

$0.00

(0.00%)

20:06
11/15/18
11/15
20:06
11/15/18
20:06
Hot Stocks
Avita Medical to hire U.S. sales team to support national launch of Recell »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDXAY

Sodexo

$0.00

(0.00%)

20:05
11/15/18
11/15
20:05
11/15/18
20:05
Downgrade
Sodexo rating change at JPMorgan »

Sodexo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATY

Cathay General

$38.83

0.91 (2.40%)

20:01
11/15/18
11/15
20:01
11/15/18
20:01
Hot Stocks
Cathay General raises quarterly dividend to 31c from 24c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SUPV

Grupo Supervielle

$8.50

0.42 (5.20%)

19:56
11/15/18
11/15
19:56
11/15/18
19:56
Downgrade
Grupo Supervielle rating change at Santander »

Grupo Supervielle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAAP

Corporacion America Airport

$8.37

0.63 (8.14%)

19:52
11/15/18
11/15
19:52
11/15/18
19:52
Hot Stocks
Corporacion America Airport reports October traffic up 4.5% »

Corporacion America…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$348.37

4.3 (1.25%)

19:43
11/15/18
11/15
19:43
11/15/18
19:43
Periodicals
Tesla aims for Model 3 output of 7K units per week in two weeks, Electrek says »

Tesla has looked to ramp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 13

    Dec

AIV

Aimco

$44.65

-0.46 (-1.02%)

19:26
11/15/18
11/15
19:26
11/15/18
19:26
Hot Stocks
Aimco says California fires have not caused material damage to company »

Apartment Investment and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$239.93

4.83 (2.05%)

19:19
11/15/18
11/15
19:19
11/15/18
19:19
Initiation
Adobe initiated at Nomura Instinet »

Nomura starts Adobe with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPWR

Ideal Power

$0.39

-0.1505 (-27.87%)

19:16
11/15/18
11/15
19:16
11/15/18
19:16
Downgrade
Ideal Power rating change at Oppenheimer »

Ideal Power downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SONO

Sonos

$14.14

0.17 (1.22%)

, SCVL

Shoe Carnival

$37.03

-1.94 (-4.98%)

19:09
11/15/18
11/15
19:09
11/15/18
19:09
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Sonos…

SONO

Sonos

$14.14

0.17 (1.22%)

SCVL

Shoe Carnival

$37.03

-1.94 (-4.98%)

BGCP

BGC Partners

$10.66

0.24 (2.30%)

SALT

Scorpio Bulkers

$5.71

0.115 (2.06%)

ESEA

Euroseas

$1.65

-0.11 (-6.25%)

NVDA

Nvidia

$202.65

5.43 (2.75%)

WSM

Williams-Sonoma

$60.60

-1.16 (-1.88%)

JWN

Nordstrom

$58.97

-2.125 (-3.48%)

AMAT

Applied Materials

$35.03

1.44 (4.29%)

HTHT

Huazhu Group

$28.59

0.64 (2.29%)

SQ

Square

$73.59

3.74 (5.35%)

NGVC

Natural Grocers

$16.66

0.06 (0.36%)

MCF

Contango Oil & Gas

$4.50

-0.19 (-4.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

  • 12

    Dec

  • 18

    Dec

DOMO

Domo

$15.96

0.47 (3.03%)

19:04
11/15/18
11/15
19:04
11/15/18
19:04
Hot Stocks
Domo unveils new product suite »

Domo, provider of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCH

PotlatchDeltic

$36.71

-0.31 (-0.84%)

19:01
11/15/18
11/15
19:01
11/15/18
19:01
Hot Stocks
PotlatchDeltic to pay special dividend of about $3.54 per share »

PotlatchDeltic announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$143.86

-0.39 (-0.27%)

18:54
11/15/18
11/15
18:54
11/15/18
18:54
Periodicals
Senator to ask Facebook about report on treatment of critics, Reuters says »

Senator Amy Klobuchar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

ALRM

Alarm.com

$48.81

0.82 (1.71%)

18:45
11/15/18
11/15
18:45
11/15/18
18:45
Hot Stocks
Alarm.com CEO sells 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

  • 05

    Dec

LAUR

Laureate Education

$14.45

0.3 (2.12%)

18:31
11/15/18
11/15
18:31
11/15/18
18:31
Syndicate
Laureate Education 12.25M share Secondary priced at $14.00 »

Credit Suisse, Barclays,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

PCG

PG&E

$17.77

-7.89 (-30.75%)

18:28
11/15/18
11/15
18:28
11/15/18
18:28
Periodicals
CPUC doesn't want PG&E to go into bankruptcy, Bloomberg says »

A California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

18:24
11/15/18
11/15
18:24
11/15/18
18:24
Periodicals
SEC investigating a company's $50M cryptocurrency sale, WSJ reports »

The SEC is investigating…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$17.77

-7.89 (-30.75%)

18:23
11/15/18
11/15
18:23
11/15/18
18:23
Hot Stocks
PG&E cut to Baa3 from Baa2 by Moody's, could be cut further »

Moody's downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMB

Limbach Holding

$8.31

-0.14 (-1.66%)

18:10
11/15/18
11/15
18:10
11/15/18
18:10
Hot Stocks
Limbach Holding lowers FY18 EBITDA view to $8M-$10M from $18M-$20M »

Backs FY18 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.